1,100
Participants
Start Date
November 25, 2013
Primary Completion Date
September 10, 2015
Study Completion Date
November 14, 2016
AFOLIA
225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Gonal-f® RFF
225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Abington Reproductive Medicine, Abington
Main Line Fertility Center, Bryn Mawr
Shady Grove Fertility RSC, Chesterbrook, PA, Chesterbrook
University of Penn, Philadelphia
Reproductive Associates of Delaware, Newark
Shady Grove Fertility RSC, Rockville
Jones Institute for Reproductive Medicine, Norfolk
Georgia Reproductive Specialists, Atlanta
FL Fertility Institution, Tampa
Fertility Associates of Memphis, Memphis
Institute for Reproductive Health, Cincinnati
In Via Fertility Specialists, Hoffman Estate
Fertility Centers of Illinois, Chicago
Center for Assisted Reproduction, Bedford
Fertility Specialists of Houston, Houston
Houston Fertility Institute, Houston
Center of Reproducitve Medicine, Webster
Texas Fertility Center, Austin
Physicians Research Group, Tempe
Nevada Center for Reproductive Medicine, Reno
HRC Fertility, Encino
Cooper Institute of Reproductive Hormonal Disorders, P.C., Marlton
Lead Sponsor
Fertility Biotech AG
INDUSTRY